Literature DB >> 23392720

Analysis of clinicopathological factors associated with bone metastasis in breast cancer.

Jing Chen1, Shu Zhu1, Xiu-Zhen Xie2, Shan-Feng Guo1, Liang-Qian Tong1, Sheng Zhou3, Ming Zhao1, Zhi-Qun Xianyu1, Xiao-Hua Zhu1, Wei Xiong4.   

Abstract

Breast cancer is the second leading cause of cancer death in women today. Once breast cancer metastasizes to bone, mortality increases. Thus, there is an urgent need to identify patients with high risk of bone metastasis, and to find predictive factors for the occurrence of bone metastasis at an earlier stage of breast cancer. Three hundred and sixty patients with pathologically proved breast cancer visiting the Department of Nuclear Medicine for whole body bone scan from January 2006 and January 2009 were investigated in this study. Clinicopathological information was obtained, which consisted of age, menopausal status, clinical staging, lymph node stage, histological grade, the expression of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2). Correlation between bone metastasis and the associated factors was tested by using the Chi-square test. A Cox multivariate analysis was used to assess the factors which independently contributed to survival after bone metastasis in breast cancer patients. Survival curves were drawn for metastasis-free interval and the independent factors which contributed to survival, using the Kaplan-Meier method. Twenty-four patients were excluded from subsequent analysis. Three hundred and thirty-six enrolled patients ranged in age from 22 to 77 years (mean, 47.8 years). ER/PR status [ER(+) vs. ER(-), χ (2)=4.328, P=0.037; ER(+)PR(+) vs. ER(+)PR(-), χ (2)=4.425, P=0.035] and histological grade (χ (2)=7.131, P=0.028) were significantly associated with bone metastasis. ER status (x (2)=8.315, P=0.004) and metastasis-free interval (χ (2)=6.863, P=0.009) were independent prognostic factors for survival in breast cancer patients with bone metastasis. Our study suggested that ER/PR status and histological grade are risk factors for the development of bone metastasis in breast cancer patients. However, ER status and metastasis-free interval are independent prognostic factors for survival in breast cancer patients with bone metastasis. Breast cancer bone metastasis has its unique characteristics, which is helpful to choose the appropriate treatment for breast cancer patients with bone metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392720     DOI: 10.1007/s11596-013-1083-1

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  14 in total

1.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

Authors:  Sherene Loi; Benjamin Haibe-Kains; Christine Desmedt; Françoise Lallemand; Andrew M Tutt; Cheryl Gillet; Paul Ellis; Adrian Harris; Jonas Bergh; John A Foekens; Jan G M Klijn; Denis Larsimont; Marc Buyse; Gianluca Bontempi; Mauro Delorenzi; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

Review 2.  Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.

Authors:  Rena Callahan; Sara Hurvitz
Journal:  Curr Opin Obstet Gynecol       Date:  2011-02       Impact factor: 1.927

Review 3.  Mechanisms in the skeletal complications of breast cancer.

Authors:  T J Martin; J M Moseley
Journal:  Endocr Relat Cancer       Date:  2000-12       Impact factor: 5.678

4.  Reappraisal of the baseline bone scan in breast cancer.

Authors:  R E Coleman; R D Rubens; I Fogelman
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

5.  Healing flare in skeletal metastases from breast cancer.

Authors:  M J Janicek; D F Hayes; W D Kaplan
Journal:  Radiology       Date:  1994-07       Impact factor: 11.105

6.  Bone metabolic markers in bone metastases.

Authors:  M Koizumi; Y Yamada; T Takiguchi; E Nomura; M Furukawa; T Kitahara; T Yamashita; H Maeda; S Takahashi; K Aiba
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

Review 8.  The changing face of breast cancer--past, present and future perspectives.

Authors:  Michael Baum
Journal:  Breast Cancer Res Treat       Date:  2002-10       Impact factor: 4.872

9.  Clinical course and prognostic factors following bone recurrence from breast cancer.

Authors:  R E Coleman; P Smith; R D Rubens
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

Authors:  M R Williams; J H Todd; I O Ellis; C S Dowle; J L Haybittle; C W Elston; R I Nicholson; K Griffiths; R W Blamey
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

View more
  7 in total

1.  Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis.

Authors:  Yuanxing Pan; Yunfei Lin; Chuan Mi
Journal:  Ann Transl Med       Date:  2021-08

2.  Chemokine (C-X-C motif) receptor 4 RNA interference inhibits bone metastasis in breast cancer.

Authors:  Heng Zeng; Wei Wei; Xiaotao Xu
Journal:  Oncol Lett       Date:  2014-04-28       Impact factor: 2.967

Review 3.  Bone metastasis risk factors in breast cancer.

Authors:  Catarina Pulido; Inês Vendrell; Arlindo R Ferreira; Sandra Casimiro; André Mansinho; Irina Alho; Luís Costa
Journal:  Ecancermedicalscience       Date:  2017-01-24

4.  Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center.

Authors:  Etoroabasi Ekpe; Asim Jamal Shaikh; Jasmit Shah; Judith S Jacobson; Shahin Sayed
Journal:  J Glob Oncol       Date:  2019-07

Review 5.  The role of general nuclear medicine in breast cancer.

Authors:  Lacey R Greene; Deborah Wilkinson
Journal:  J Med Radiat Sci       Date:  2015-02-12

6.  Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice.

Authors:  Jing Chen; Shu Zhu; Liangqian Tong; Jiansha Li; Fei Chen; Yunfeng Han; Ming Zhao; Wei Xiong
Journal:  BMC Cancer       Date:  2014-02-21       Impact factor: 4.430

Review 7.  Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data.

Authors:  Hongwei Zhang; Wei Zhu; Ewelina Biskup; Weige Yang; Ziang Yang; Hong Wang; Xiaochun Qiu; Chengjiao Zhang; Guangxia Hu; Guangfu Hu
Journal:  J Bone Oncol       Date:  2018-02-03       Impact factor: 4.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.